Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabine M J Straus

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Drug Safety|November 11, 2017
Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic DrugsGiampiero Mazzaglia, Sabine M J Straus, Peter Arlett, et al.
Drug Safety|October 11, 2011
Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment ReportsArna H Arnardottir, Flora M Haaijer-Ruskamp, Sabine M J Straus, et al.
British Journal of Clinical Pharmacology|April 20, 2011
Additional safety risk to exceptionally approved drugs in Europe?Arna H Arnardottir, Flora M Haaijer-Ruskamp, Sabine M J Straus, et al.
British Journal of Clinical Pharmacology|December 4, 2014
Understanding drug preferences, different perspectivesPeter G M Mol, Arna H Arnardottir, Sabine M J Straus, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Drug Safety|November 11, 2017
Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic DrugsGiampiero Mazzaglia, Sabine M J Straus, Peter Arlett, et al.
Drug Safety|October 11, 2011
Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment ReportsArna H Arnardottir, Flora M Haaijer-Ruskamp, Sabine M J Straus, et al.
British Journal of Clinical Pharmacology|April 20, 2011
Additional safety risk to exceptionally approved drugs in Europe?Arna H Arnardottir, Flora M Haaijer-Ruskamp, Sabine M J Straus, et al.
British Journal of Clinical Pharmacology|December 4, 2014
Understanding drug preferences, different perspectivesPeter G M Mol, Arna H Arnardottir, Sabine M J Straus, et al.
Pageof 1